文献速递MDS 与骨髓增殖性肿瘤

我如何管理不可分类的骨髓增殖性肿瘤:2022年及以后的实践方法

How I manage myeloproliferative neoplasm-unclassifiable: Practical approaches for 2022 and beyond.
PubMed 文献 · Br J Haematol · 2022-02-22

不可分类的骨髓增殖性肿瘤(MPN-U)是一种罕见、定义不清且异质性的MPN,严格按WHO标准约占所有MPN的5%。诊断需动态评估以重新分类,患者面临缺乏共识监测和治疗指南、验证的预后标志物及获批疗法,且被排除临床试验。本文提供MPN-U的当代综述及四例示例病例,分享临床挑战的集体建议方法。

要点

  • 严格按WHO标准,MPN-U约占所有MPN的5%。
  • 诊断MPN-U需动态审查以评估能否重新分类为其他MPN实体。
  • MPN-U患者缺乏共识监测和治疗指南、验证的预后标志物及获批疗法,且被排除临床试验。

核心结论

  • MPN-U是一种罕见、定义不清且异质性的MPN,诊断后需动态审查以重新分类,患者面临缺乏指南、预后标志物和获批疗法等多重挑战。

研究设计与样本

  • 本文为当代综述,并附四例示例病例提供临床挑战的集体建议方法。

主要发现

  • 严格按WHO标准,MPN-U约占所有MPN的5%。
  • MPN-U具有侵袭性临床病程和转化的内在风险,但哪些患者及何时在慢性期治疗仍难以确定。
  • 尽管血栓风险显著,但尚无系统 primary 血栓预防的共识。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative neoplasm (MPN)-unclassifiable (MPN-U) or not otherwise specified represents a rare, poorly defined and heterogeneous group of MPNs. Disease incidence is difficult to define but likely represents close to 5% of all MPNs when strict World Health Organisation (WHO) criteria are applied. Dynamic review over time is required to assess if the disease can be re-classified into another MPN entity. A diagnosis of MPN-U leads to many challenges for both the patient and physician alike including lack of agreed monitoring and therapeutic guidelines, validated prognostic markers and licenced therapies coupled with exclusion from clinical trials. MPN-U has an inherent risk of an aggressive clinical course and transformation in some but who, and when to treat in the chronic phase, including identifying who may require more aggressive therapy at an earlier stage, remains elusive. Moreover, despite the significant thrombotic risk, there is no agreement on systematic primary thromboprophylaxis. We hereby provide a contemporary overview of MPN-U in addition to four illustrative cases providing our collective suggested approaches to clinical challenges.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. McLornan DP, Hargreaves R, Hernández-Boluda JC, et al. How I manage myeloproliferative neoplasm-unclassifiable: Practical approaches for 2022 and beyond. Br J Haematol. 2022. PMID: 35191542. doi:10.1111/bjh.18087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。